Group 1 - MoonLake Immunotherapeutics announced topline results from the S-OLARIS Phase 2 trial of sonelokimab (SLK) in patients with axial spondyloarthritis (axSpA), demonstrating significant clinical benefits [2][5][6] - In the S-OLARIS trial, 81% of patients treated with SLK achieved an ASAS40 response at Week 12, indicating a clinically meaningful improvement [2][5] - The trial also showed over 80% of patients achieved a clinically important improvement as per ASDAS-CRP score, with significant reductions in inflammation and osteoblast activity observed through PET imaging [2][5][6] Group 2 - MoonLake reported financial results for Q4 and the year ended December 31, 2025, with cash and equivalents totaling $394 million, expected to fund operations into the second half of 2027 [7] - Research and development expenses for Q4 2025 were $56 million, down from $60.6 million in the previous quarter, while general and administrative expenses decreased to $9.2 million from $10.8 million [7] - The company amended its debt facility with Hercules Capital, drawing down $25 million, with up to $400 million in non-dilutive funds available for future needs [7] Group 3 - An Investor Day webcast is scheduled for February 23, 2026, where the company will present the S-OLARIS data and discuss upcoming milestones, including the Type B FDA Meeting outcomes for hidradenitis suppurativa [8][12] - The company is pursuing multiple indications for sonelokimab, including hidradenitis suppurativa, psoriatic arthritis, and palmoplantar pustulosis, with significant market opportunities projected [11][27][29]

Company Overview - MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biopharmaceutical company focused on developing innovative Nanobody therapies for inflammatory skin and joint diseases. Its main asset, sonelokimab, targets IL-17A and IL-17F to alleviate inflammation in conditions such as hidradenitis suppurativa and psoriatic arthritis [4]. Analyst Ratings - Goldman Sachs downgraded MLTX from Neutral to Sell, raising the price target to $10 from $8. The firm highlighted the advancement of sonelokimab into Phase 3 for palmoplantar pustulosis as a potential opportunity but expressed concerns about significant approvability risks in hidradenitis suppurativa due to the failure of VELA-2 to meet its primary endpoint [2]. - H.C. Wainwright increased the price target for MoonLake Immunotherapeutics to $32 from $26 while maintaining a Buy rating, noting that the outcome of the FDA Type B meeting provides a clear path toward regulatory registration [3]. Investment Considerations - While there is potential for MLTX as an investment, some analysts believe that certain AI stocks present greater upside potential with less downside risk [5].

Core Insights - The FDA has granted Fast Track designation for sonelokimab (SLK) for the treatment of moderate-to-severe palmoplantar pustulosis (PPP), highlighting the significant unmet medical need in this area [1][3][5] - MoonLake Immunotherapeutics plans to submit a Biologic License Application (BLA) for SLK in hidradenitis suppurativa (HS) in the second half of 2026, following positive FDA interactions [1][5] - An Investor Day is scheduled for February 23, 2026, where the company will provide updates on clinical and regulatory progress across multiple indications, including new data from the S-OLARIS program for SLK in axial spondyloarthritis (axSpA) [1][4][5] Fast Track Designation - Fast Track is an FDA program aimed at expediting the development and review of drugs for serious conditions with unmet medical needs, allowing for earlier patient access to important new therapies [2] - The designation for SLK in PPP reflects the severe burden of the condition and the lack of approved treatments, enabling a streamlined development process [3][5] - Benefits of the Fast Track designation include more frequent FDA interactions, potential eligibility for Accelerated Approval and Priority Review, and the possibility of a Rolling Review for BLA submissions [3][5] Clinical Development and Upcoming Milestones - The Phase 2 LEDA trial for SLK in PPP showed significant clinical benefits, with a mean percent change in the Palmoplantar Psoriasis Area and Severity Index (PPPASI) of 64% at week 16, and 39% of patients achieving a ≥75% reduction [19] - The upcoming Phase 3 program for SLK in PPP is expected to benefit from the Fast Track designation, allowing for more efficient development pathways [5] - Key upcoming milestones include the primary endpoint readout of the Phase 2 S-OLARIS trial in axSpA in February 2026, and the BLA submission for HS in H2 2026 [15][5] Company Overview - MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing sonelokimab, a novel investigational Nanobody targeting inflammatory diseases [9] - The company aims to address significant unmet needs in conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis, which affect millions globally [9][35] - Sonelokimab works by inhibiting IL-17A and IL-17F, key drivers of inflammation in these diseases [12][9]

As filed with the Securities and Exchange Commission on January 16, 2026. Registration No. 333-291993 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________________ HELIX ACQUISITION CORP. III (Exact name of registrant as specified in its charter) ______________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdict ...

Economic Indicators - The US January Philadelphia Fed business outlook survey increased by +21.4 to a four-month high of 12.6, surpassing expectations of -1.4 [1] - The US January Empire manufacturing survey rose by +11.4 to 7.7, exceeding expectations of 1.0 [1] - Weekly initial unemployment claims in the US unexpectedly fell by -9,000 to a six-week low of 198,000, contrary to expectations of an increase to 215,000 [1] Stock Market Performance - Stock indexes closed higher, with the S&P 500 Index up +0.26%, the Dow Jones up +0.60%, and the Nasdaq 100 up +0.32% [5] - A rally in chip makers was led by Taiwan Semiconductor Manufacturing Co (TSMC), which forecasted stronger-than-expected Q1 sales and increased its 2026 capital expenditure forecast to $52 billion-$56 billion from $40.9 billion in 2025 [4] - Energy producers and service providers experienced a sell-off as WTI crude oil prices dropped more than -4% [13] Company-Specific Developments - Morgan Stanley reported Q4 FICC sales and trading revenue of $3.67 billion, exceeding the consensus of $3.55 billion, leading to a +5% increase in its stock price [16] - Goldman Sachs reported Q4 FICC sales and trading revenue of $3.11 billion, stronger than the consensus of $2.95 billion, resulting in a +4% increase in its stock price [17] - Calavo Growers saw its stock rise by more than +13% after Mission Produce agreed to acquire the company for about $27 a share in cash and stock [15] Earnings Expectations - The Q4 earnings season is set to begin, with S&P earnings growth expected to climb by +8.4% in Q4, and +4.6% excluding the Magnificent Seven megacap technology stocks [7] - The market is currently discounting a 5% chance of a -25 basis point rate cut at the FOMC's next meeting on January 27-28 [7]

The Supreme Court didn’t rule on challenges to President Trump’s tariffs on Wednesday. The court did not say when it will issue its next opinions but could schedule more decisions for next Tuesday and Wednesday, when the justices are again in session.President Trump told Reuters that he "has no plans" to fire Fed Chair Powell despite a Justice Department probe into the central bank's renovation.Atlanta Fed President Raphael Bostic said the Fed needs to stay restrictive because he expects inflation pressures ...

Economic Indicators - The US January Philadelphia Fed business outlook survey rose by +21.4 to a four-month high of 12.6, exceeding expectations of -1.4 [2] - The US January Empire manufacturing survey general business conditions increased by +11.4 to 7.7, also stronger than expectations of 1.0 [2] - Weekly initial unemployment claims unexpectedly fell by -9,000 to a 6-week low of 198,000, contrary to expectations of an increase to 215,000 [3] Stock Market Performance - Stocks gained today, driven by positive economic indicators, including the drop in jobless claims and the rise in business outlook surveys [4] - The S&P 500 Index rose by +0.55%, the Dow Jones Industrials Index increased by +0.20%, and the Nasdaq 100 Index was up by +1.00% [6] - Chip makers rallied after Taiwan Semiconductor Manufacturing Co (TSMC) forecasted stronger-than-expected Q1 sales and increased its 2026 capital expenditure forecast to $52 billion-$56 billion from $40.9 billion in 2025 [5] Company-Specific Developments - TSMC's positive outlook has boosted confidence in the sustainability of artificial intelligence demand, leading to significant gains in related stocks [5] - Penumbra's stock rose by more than +12% after Boston Scientific agreed to acquire the company for approximately $14.5 billion, or $374 a share [15] - Black Rock reported Q4 net inflows of $341.71 billion, surpassing the consensus of $287.49 billion, leading to a stock increase of more than +4% [16] Sector Movements - Defense stocks declined due to easing geopolitical risks in Iran, with companies like Huntington Ingalls Industries and Northrop Grumman down more than -2% [13] - Energy producers faced pressure as WTI crude oil prices fell by more than -4%, impacting stocks like APA Corp and Devon Energy [14]

Group 1 - MoonLake Immunotherapeutics, trading under the symbol MLTX, is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [1][5] - Goldman Sachs downgraded MLTX to "Sell" from "Neutral," with a price target of $10, indicating a potential decrease of approximately -42.56% from the current price of $17.41 [1][5] - The company has made significant progress with its lead product, Sonelokimab (SLK), receiving positive feedback from the FDA regarding its Biologic License Application (BLA) for treating Hidradenitis Suppurativa (HS) [2][5] Group 2 - The FDA confirmed that MoonLake could use existing trial data to establish SLK's effectiveness, allowing the company to proceed with the BLA submission in the second half of 2026 [3][5] - This regulatory clarity is crucial for potentially expediting the approval process for SLK [3] - MoonLake plans to discuss the FDA feedback and other opportunities for SLK during an Investor Day on February 23, 2026 [3] Group 3 - Currently, MLTX is priced at $17.41, with a recent increase of $0.31, or approximately 1.81% [4] - The stock has fluctuated between $17.02 and $17.91 today, with a market capitalization of around $1.1 billion and a trading volume of 1,892,708 shares [4] - Over the past year, MLTX has seen a high of $62.75 and a low of $5.95 [4]

Core Viewpoint - MoonLake Immunotherapeutics (NASDAQ: MLTX) is experiencing mixed market reactions following a downgrade from Goldman Sachs, yet positive developments regarding FDA feedback may enhance its prospects in the biopharmaceutical sector [1][6]. Group 1: Company Overview - MoonLake Immunotherapeutics focuses on developing innovative therapies for inflammatory diseases [1]. - The company has a market capitalization of approximately $1.1 billion [5]. Group 2: Stock Performance - MLTX shares surged by 9.6%, closing at $15.72, up from a previous close of $14.34, despite a downgrade to Sell by Goldman Sachs [2][6]. - The stock has fluctuated between $17.02 and $17.91 recently, with a high of $62.75 and a low of $5.95 over the past year [5]. Group 3: Analyst Ratings - HC Wainwright reaffirmed a Buy rating and raised its price target to $32, indicating strong confidence in the stock's potential [4]. - Needham also maintained a Buy rating with a price target of $20, further supporting a positive outlook for the company [4]. Group 4: Regulatory Developments - Favorable feedback from the FDA suggests that MoonLake may file for skin drug approval without new clinical trials, potentially expediting the Biologics License Application process [3][6].

Core Insights - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Friday [1] Company Highlights - CG Oncology Inc (NASDAQ:CGON) saw its shares rise by 21.8% to $51.05 after announcing an expedited timeline for topline data from the Phase 3 PIVOT-006 clinical trial, now expected in the first half of 2026 [1][2] - Rich Sparkle Holdings Ltd (NASDAQ:ANPA) surged 113.6% to $51.70 following a $39 million offering of 3 million ordinary shares at $13 per share [3] - NovaBay Pharmaceuticals Inc (NYSE:NBY) increased by 34.4% to $12.81 [3] - Quanterix Corp (NASDAQ:QTRX) gained 29.3% to $8.42 after naming Everett Cunningham as President and CEO, effective January 19 [3] - MoonLake Immunotherapeutics (NASDAQ:MLTX) rose 21.7% to $17.45 after receiving FDA feedback on its clinical evidence strategy for Sonelokimab in Hidradenitis Suppurativa [3] - Enliven Therapeutics Inc (NASDAQ:ELVN) increased by 21.5% to $28.24, sharing positive initial data from its Phase 1b ENABLE trial for ELVN-001 in chronic myeloid leukemia [3] - Aeva Technologies Inc (NASDAQ:AEVA) surged 21.2% to $20.47 [3] - Loandepot Inc (NYSE:LDI) rose 20.1% to $2.93 [3] - ASP Isotopes Inc (NASDAQ:ASPI) increased by 19.7% to $7.71 [3] - Allogene Therapeutics Inc (NASDAQ:ALLO) gained 19.5% to $1.78 [3] - Opendoor Technologies Inc (NASDAQ:OPEN) rose 19.2% to $7.67 following a new housing market proposal by President Donald Trump [3] - Liquidia Corp (NASDAQ:LQDA) jumped 14% to $36.22 after announcing preliminary full-year 2025 YUTREPIA net sales [3] - Vistra Corp (NYSE:VST) gained 13.1% to $170.34 after entering into 20-year power purchase agreements for zero-carbon nuclear energy to support Meta's operations [3] - Oklo Inc (NYSE:OKLO) rose 12.6% to $109.95 after announcing an agreement with Meta for a 1.2 gigawatt power campus [3] - Applied Digital Corp (NASDAQ:APLD) surged 11.8% to $35.72, reporting strong second-quarter results and advanced talks with a new hyperscaler tenant [3] - AST SpaceMobile Inc (NASDAQ:ASTS) gained 10% to $99.65 [3] - SanDisk Corp (NASDAQ:SNDK) increased by 9.6% to $366.93 [3] - Mirion Technologies Inc (NYSE:MIR) rose 9.5% to $26.56 [3] - TTM Technologies Inc (NASDAQ:TTMI) gained 9.1% to $72.94 [3] - SoundHound AI Inc (NASDAQ:SOUN) rose 8.5% to $11.96 [3] - Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) gained 8.3% to $112.64, with B. Riley Securities maintaining a Buy rating and raising the price target from $105 to $128 [3]